$CARSGEN-B(02171)$ announced that its Claudin18.2 CAR-T Shuriki Olinse Injection achieved preliminary positive results in the Phase 11 clinical trial for gastric cancer in China, demonstrating immense potential and commercial value in treating both hematological and solid tumors.
I declare it today's top-performing Hong Kong stock. I made the decision to buy this stock last Friday, and today I’m seeing the returns.
I’m truly grateful for the choice I made!
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
